Navigation Links
Landauer, Inc. Reports Fiscal 2009 Third Quarter Results
Date:8/4/2009

GLENWOOD, Ill., Aug. 4 /PRNewswire-FirstCall/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation monitoring services, today reported financial results for the three and nine months ended June 30, 2009.

Fiscal 2009 Third Quarter Highlights

  • Revenue grew 7 percent to $23.5 million on continued global demand for InLight products and increased domestic badge revenues.
  • Gross profit grew 4 percent to $15.6 million on increased revenue.
  • Effective tax rate declined to 30 percent due primarily to changes in Illinois state tax law and tax benefit of funding frozen pension plan.
  • Net income grew 13 percent to $6.5 million, or $0.70 per diluted share.

"We are pleased with this quarter's financial results, which were driven substantially by InLight sales both domestically and abroad," stated Bill Saxelby, President and CEO of Landauer. "During the quarter we made significant InLight product placements across several markets we have targeted for growth including the U.S. military, the first responder market, and patient monitoring. In addition, we continued to drive global expansion through the continuation of our relationship with Health Canada and placement of InLight products into Southeast Asia through our joint venture with Nagase-Landauer."

"The continued acceptance of our InLight suite of products, success of our international expansion initiative and adoption of our offerings in the medical, nuclear and military markets affirm the long-term growth prospects for our business. We have also made significant progress in our current systems initiative, delivering successfully on several important milestones during the quarter."


'/>"/>

SOURCE Landauer, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2009 Results
2. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Second Quarter 2009 Results
3. Landauer, Inc. Declares Regular Cash Dividend
4. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2009 Results
5. Landauer, Inc. Increases Regular Cash Dividend and Declares First Quarter Payment
6. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2008 Results
7. Landauer, Inc. Declares Regular Cash Dividend
8. Landauer, Inc. Declares Regular Cash Dividend
9. Landauer, Inc. Reports Record Results for Second Quarter
10. Landauer, Inc. Declares Regular Cash Dividend
11. Landauer, Inc. Reports Strong Fiscal 2008 First Quarter Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ng medical device software engineering consulting ... certification. A relatively few medical device so...achieved ISO 13485 certification. Many medical dev... to other ISO standards as well. However, it is so...ing consulting firm to achieve the rigorous qualit...
(Date:12/2/2009)...Newswire/ -- A randomized, controlled study compar...nvasive treatment called percutaneous disc decompr...ile both treatments help patients in the short run...up to two years later. Results of the study, the f...al meeting of the Radiological Society of North Am...
(Date:12/2/2009)...asound of suspicious areas of the breast, includin...ternative to invasive biopsies for women under age...ented today at the annual meeting of the Radiologi...rming high-quality breast ultrasound, we can reduc...iagnostic procedures in young women," said senior ...
(Date:12/1/2009)...ate Christ Medical Center in Oak Lawn, Ill. has be...nter and the first for Chicago’s south and s... hospital’s plans today (December 1) by the ...rd. , Springfield, Ill. (...Lawn, Ill. has become the state’s newest kid...
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, The Future of Monoclonal Antib...hmarking, Product Pipeline and Deals Analysis ,...e-of-Monoclonal-Antibodies---Market-Forecasts-to-2...Deals-Analysis.html ,, Summary ,, The au...
Breaking Medicine News(10 mins):Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13
...ect of hormone replacement therapy may be inhibite...eroidal anti-inflammatory pain killer, report rese...f Pennsylvania. The researchers examined t...coronary heart disease and compared them with 7,00...
...ople another reason to quit smoking, by finding th...oping depression in comparison to those who never...kers who have quit have an elevated risk of depres... style and successful smoking cessation in long ru...
...that vegetarian diet reduces risk of colon cancer ...up as appetizer reduces food intake by about 20 pe...ife factors like choosing your diet regimen or ord...t to find out whether a vegetarian diet is associa...
...lthcare scenario has emerged a heartening developm...ated Paromomycin IM injection manufactured by the...fit drug firm, for inclusion in its Model List for...rasitic disease after malaria. It is a sy...
...ests using gene sequencing is able to help confirm...ns and patients the tools for much more accurate ...e a group of more than 40 inherited and potentiall...ucts that damage organs and tissues. The g...
...t men with chronic gum disease periodontitis, may ...ss of whether they smoke. Periodontitis is...a, though recent evidence suggests the involvement... Roswell Park Cancer Institute, Buffalo. A...
Other Medicine News:Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 3Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 4Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
(Date:12/1/2009)..., BELLEVUE, Wash., Dec. 1 /PRNewswire-FirstCall/...g online retailer of health, beauty, vision, and p...y was its best day ever as customer orders were th...the drugstore.com and Beauty.com web stores fe...and their largest gift selection yet. ,, (Logo:...
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker.... available in its catalogue: ,, Direct to Cons...t and Future Market Outlook, Regulatory Landscape ...om/p0166813/Direct-to-Consumer-DTC-Advertising-in-...k-Regulatory-Landscape-and-Case-Studies.html ,...
(Date:12/1/2009)...ologist reports 90 percent radiation reduction in ...-USNewswire/ -- Dr. James Earls, a radiologist fro...hington, D.C. will present the findings of a study...f radiation heart patients received from CT scans ... Dr. Earls will present the study to the annual me...
Breaking Medicine Technology:drugstore.com, inc. Has Best Day Ever on Cyber Monday 2drugstore.com, inc. Has Best Day Ever on Cyber Monday 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8Radiation Reduction in Heart CT Scans Reported in Study 2EGEN Inc Announces the Promotion of Khursheed Anwer Ph D to President and Chief Scientific Officer 12452 1EGEN Inc Announces the Promotion of Khursheed Anwer Ph D to President and Chief Scientific Officer 12452 2GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands 47821 1GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands 47821 2Small molecules mimic natural gene regulators 8713 1Small molecules mimic natural gene regulators 8713 2
...ne payment to Pharmasset , , PRINCETON, N.J., Apr...e (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today a...a Phase IIb study of R7128, the nucleoside polymer... treatment of chronic hepatitis C (HCV). The trial...of R7128 in combination with Roche,s PEGASYS(R) (p...
...for Blinatumomab , , NEW YORK, April 24 Micromet...any developing novel, proprietary antibodies for t...e diseases, today held an R&D Day for investor...ork City. , , The presentations highlighted sig...TE antibody platform and included updates on: , ,...
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
PulseOx 7500 Pulse Oximeter
Merlin Patient Care System
Safire Bi-directional Ablation Catheter
VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System
Medicine Products: